Michelle Brady remembers how much she loved the life of her daughter Addie.
Key points:
- Addie Brady was diagnosed with cancer at the age of 9 and 14
- Genetic testing revealed that he had an inherited mutation in the TP53 gene, known as the “guardian of the genome.”
- Researchers have high hopes for what precision medicine can do for those at risk of cancer
Although Addie received cancer treatment at age nine, Michelle says she was selfless and brave.
“She was an amazing little girl. Very bright, very, very pretty. I know a lot of parents say that about their kids, but it really was.”
Addie had a rare form of bone cancer. Her tibia had to be replaced with a prosthesis in her leg and she spent months in the hospital undergoing harsh chemotherapy. But it wouldn’t be his last brush with cancer.
“When she was 14, she got up one morning and right away, there was no sign of that, five years after her first cancer, she couldn’t speak and she had a seizure,” Michelle said. he says.
“And an ambulance rushed her to the hospital. A couple of days later, we were told she had an inoperable brain tumor.”
Addie had an inherited mutation in the TP53 gene, which is known as the “guardian of the genome.” (Provided by: Michelle Brady)
Michelle knew something else was going on. It made no sense that her young daughter could have two different cancers in such a short time.
Genetic testing revealed that Addie had Li Fraumeni Syndrome or LFS.
It is a mutation inherited from the TP53 gene, which is known as the “guardian of the genome” because it prevents cancers from forming. But for people with LFS, this process goes wrong.
“Addie knew the severity of the cancer because at the age of nine she had experienced it,” says Michelle.
“I had seen the children I had been in the room with lose their lives due to cancer.
“During the time before we lost her, she probably asked me twice,‘ Am I going to die, Mom? And it was one of the hardest questions I’ve ever had to answer. “
The cancer eventually moved to Addie’s spine and Michelle remembers how hard the last months of Addie’s life were.
“It was heartbreaking to see his experience … and not be able to do anything about it.”
Space to play or pause, M to mute, left and right arrows to search, up and down arrows for volume. Listening time: 28 minutes 36 seconds 28 m
Addie died in February 2018, at just 16 years old.
Although LFS is usually inherited, Addie had what is known as a de novo mutation, meaning she was the first person in the family to carry the mutation.
In recent decades, many hereditary mutations have been discovered that put people at risk for cancer.
There are genetic changes that occur in all cancers, often due to lifestyle and environmental factors. But these genetic changes are inherited, not acquired.
An inherited genetic mutation does not guarantee that cancer will develop, but it does put people at a much higher risk, often at a younger age. These hereditary mutations are behind 5-10% of all cancers.
Doctors seeking “targeted treatments”
Dr. Mark Pinese of the Children’s Cancer Institute leads a team of personalized medicine that studies inherited and new genetic variants that put some children at risk for cancer.
“If we can identify those children who are at risk for cancer, in the future we could have … relatively minor drugs that they can take, that will eliminate their risk … that they just don’t develop cancer at all,” says Dr. Pinese.
“And that for us is the ultimate goal, and much better than a cure.”
Researchers like Dr. Pinese have high hopes for what precision medicine can do for those at risk for cancer.
Currently, the treatment of childhood cancer is often harsh and unspecific, because much of the research so far has been done on adults.
“Very sadly, many children who survive cancer do so with long-term side effects,” says Dr. Pinese.
“These can be lifelong effects on your fertility, on your growth and development, on your learning.
“If we can find specific treatments, we believe this will also reduce side effects.”
“We call it scanning anxiety”
Another tool used is surveillance, with a clinical trial being conducted in several states in Australia.
Known as GCOS, it uses MRIs and other surveillance for people at high risk of developing cancer, especially multiple types of cancer, such as those with Li Fraumeni syndrome.
“If we take a very active approach, we can make a difference, even in a condition that has as high a risk as LFS,” says clinical geneticist professor Paul James, director of the Family Cancer Center at the Peter Cancer Center. MacCallum. and Royal Melbourne Hospital.
Professor Paul James says the previously fatalistic view of genetic cancers is changing. (Provided by: Peter MacCallum Cancer Center)
Anna Murphy, from NSW, lives with a rare mutation in the BAP1 gene that puts her at risk for multiple cancers and participates in the trial.
Anna has already had cancer three times, but none was related to the mutation.
“[My son] I was only six years old when I was diagnosed with cancer. [He] he saw his mother sick, “he says.
“My biggest fear was that my son would have it (the gene mutation). And unfortunately, he has it.
“But as I told him, we have to think of it as a blessing that we know about and that we are both experiencing.
“So if something appears or reappears in some way, it will be detected soon.”
Anna Murphy now has annual full body scans. (Provided by: Anna Murphy)
Anna does annual full body MRIs. While she is grateful to be part of the trial, she says the constant threat of cancer weighs heavily on her.
“We call it ‘scan-xiety.’ I mean it will always be there, that anxiety in the back of your head like, ‘Oh, what if he comes back?’
“It’s like you look in the mirror and see the scars from the surgery. I don’t go a day without thinking about it.”
Before there was a view in medicine that knowing these genetic risks was often useless because not enough was known about how to prevent or treat associated cancers.
But Professor James says this is changing.
“This fatalistic view has really been replaced by a vision that if we know who is at risk, there is so much more we can do.”
But no matter how far precision medicine has come, it is still in its infancy. Much of what is known about hereditary risk focuses on single-gene mutations.
Professor James says researchers are also focusing their attention on how multiple genes interact with each other.
“So instead of the risk being due to a large genetic failure that occurs in a single gene, we are starting to think about how genetic variations in the genome begin to interact with each other.
“It’s known as polygenic risk, and that’s just starting to appear as something we’re starting to see, at least in the realm of research.”
Meanwhile, Michelle Brady continues her daughter Addie’s legacy by supporting families and researching hereditary cancer syndromes like LFS.
“A lot of people say to me, ‘how do you do it? How do you do it?’
“And I do it because I know she wouldn’t want me to go on all her life just crying over her death.
“She would like me to do something about what happened to her.”
Michelle Brady says she continues Addie’s legacy supporting hereditary cancer research. (Photographed by Michelle Brady)
Health in your inbox
Get the latest ABC-wide health news and information.